Home › AdComm

FDA advisory committee calendar

Page updated October 11, 2026·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

This page lists 2 FDA advisory committee meetings with a hand-sourced vote (July 2026), and every one of the 187 drug and biologic advisory committee meetings the FDA announced in the Federal Register since January 2020, each linked to its notice. An advisory committee vote is a recommendation to the FDA, which is not bound by it and has gone against it before.

Upcoming FDA advisory committee (AdComm) meetings that review biotech drugs and biologics, the panel vote that often moves the stock more than the PDUFA itself. Sourced from FDA Federal Register notices. Meetings are announced ~4-6 weeks ahead, so this fills in as the FDA schedules them.

Meetings & results

CTGTACCAPR · Jul 29, 2026Deramiocel (CAP-1002): Duchenne muscular dystrophy (DMD) · ✗ voted 3-9 against · FR 2026-13096 CTGTACREPL · Jul 30, 2026Vusolimogene oderparepvec (RP1) + nivolumab: Advanced melanoma · ✓ voted 10-3 favorable · FR 2026-13810

Primary source: the FDA Advisory Committee Calendar. AdComm votes are advisory; the FDA makes the final decision at the PDUFA date.

Companies on this page

Every company listed above, with its full catalyst history, past FDA decisions and measured run-up into each one.

CAPR REPL

FDA advisory committee meetings, 2020 to 2026: 187 Federal Register notices

Every drug and biologic advisory committee meeting the FDA announced in the Federal Register since January 2020, with the meeting date the notice states. Notices only: which product a meeting reviewed, and any vote, are on the FDA's meeting page and are not restated here; votes we cite are sourced by hand in the table above. Medical-device panels are not listed. Cancelled and postponed meetings are marked.

2026 · 11 notices

Meeting date	Committee	Federal Register notice
Oct 30, 2026	Dermatologic and Ophthalmic Drugs Advisory Committee	FR 2026-19700, published 2026-09-25
Oct 1, 2026	Vaccines and Related Biological Products Advisory Committee	FR 2026-18349, published 2026-09-09
Sep 16, 2026	Pediatric Advisory Committee (PAC)	FR 2026-15149, published 2026-07-28
Jul 30, 2026	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2026-13810, published 2026-07-08 · vote recorded above: REPL
Jul 29, 2026	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2026-13096, published 2026-06-29 · vote recorded above: CAPR
·	Cellular, Tissue, and Gene Therapies Advisory Committee (amended notice)	FR 2026-15016, published 2026-07-24
Jul 23 and Jul 24, 2026	Pharmacy Compounding Advisory Committee	FR 2026-07361, published 2026-04-16
Jun 18, 2026	Vaccines and Related Biological Products Advisory Committee	FR 2026-10321, published 2026-05-22
May 28, 2026	Vaccines and Related Biological Products Advisory Committee	FR 2026-08122, published 2026-04-27
Apr 30, 2026	Oncologic Drugs Advisory Committee	FR 2026-04497, published 2026-03-09
Mar 12, 2026	Vaccines and Related Biological Products Advisory Committee	FR 2026-02787, published 2026-02-12

2025 · 11 notices

Meeting date	Committee	Federal Register notice
Nov 13, 2025	Pediatric Advisory Committee (PAC)	FR 2025-19281, published 2025-10-02
Nov 6, 2025	Digital Health Advisory Committee	FR 2025-17651, published 2025-09-12
Oct 9, 2025	Vaccines and Related Biological Products Advisory Committee	FR 2025-18185, published 2025-09-19
Jul 18, 2025	Psychopharmacologic Drugs Advisory Committee	FR 2025-10989, published 2025-06-17
Jul 17, 2025	Oncologic Drugs Advisory Committee	FR 2025-10855, published 2025-06-16
Jul 9, 2025	Pediatric Advisory Committee (PAC)	FR 2025-10749, published 2025-06-13
May 22, 2025	Vaccines and Related Biological Products Advisory Committee	FR 2025-08083, published 2025-05-08
May 20 and May 21, 2025	Oncologic Drugs Advisory Committee	FR 2025-08060, published 2025-05-08
Feb 24, 2025	Cardiovascular and Renal Drugs Advisory Committee	FR 2024-31309, published 2024-12-30
Feb 5, 2025	Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	FR 2024-28811, published 2024-12-09
Jan 10, 2025	Anesthetic and Analgesic Drug Products Advisory Committee	FR 2024-28210, published 2024-12-02

2024 · 30 notices

Meeting date	Committee	Federal Register notice
Dec 12, 2024	Vaccines and Related Biological Products Advisory Committee	FR 2024-24713, published 2024-10-24
Dec 4, 2024	Pharmacy Compounding Advisory Committee	FR 2024-24828, published 2024-10-25
Nov 21, 2024	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2024-22561, published 2024-10-02
Nov 20, 2024	Digital Health Advisory Committee	FR 2024-21074, published 2024-09-17
Nov 19, 2024	Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee	FR 2024-17752, published 2024-08-09
Oct 31, 2024	Endocrinologic and Metabolic Drugs Advisory Committee	FR 2024-22570, published 2024-10-02
Oct 30, 2024	Patient Engagement Advisory Committee	FR 2024-19323, published 2024-08-28
Oct 29, 2024	Pharmacy Compounding Advisory Committee	FR 2024-21241, published 2024-09-18
Oct 10, 2024	Cardiovascular and Renal Drugs Advisory Committee	FR 2024-20062, published 2024-09-06
Oct 10, 2024	Vaccines and Related Biological Products Advisory Committee	FR 2024-21431, published 2024-09-19
Oct 7, 2024	Science Board to the Food and Drug Administration Advisory Committee	FR 2024-18263, published 2024-08-15
Sep 26, 2024	Oncologic Drugs Advisory Committee	FR 2024-18970, published 2024-08-23
Sep 20, 2024	Vaccines and Related Biological Products Advisory Committee	FR 2024-18617, published 2024-08-20
Sep 18, 2024	Pediatric Advisory Committee	FR 2024-16618, published 2024-07-29
Sep 13, 2024	Gastrointestinal Drugs Advisory Committee	FR 2024-17926, published 2024-08-12
Sep 9, 2024	Antimicrobial Drugs Advisory Committee	FR 2024-17642, published 2024-08-08
Aug 2, 2024	Genetic Metabolic Diseases Advisory Committee	FR 2024-15127, published 2024-07-10
Jul 25, 2024	Oncologic Drugs Advisory Committee	FR 2024-12532, published 2024-06-07
Jun 10, 2024	Peripheral and Central Nervous System Drugs Advisory Committee	FR 2024-10051, published 2024-05-08
Jun 5, 2024	Vaccines and Related Biological Products Advisory Committee (amended notice)	FR 2024-11216, published 2024-05-22
Jun 4, 2024	Psychopharmacologic Drugs Advisory Committee	FR 2024-10053, published 2024-05-08
May 24, 2024	Endocrinologic and Metabolic Drugs Advisory Committee	FR 2024-09158, published 2024-04-29
May 22, 2024	Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	FR 2024-07273, published 2024-04-05
May 16, 2024	Vaccines and Related Biological Products Advisory Committee	FR 2024-04523, published 2024-03-04
May 9, 2024	Blood Products Advisory Committee	FR 2024-05074, published 2024-03-11
Apr 12, 2024	Oncologic Drugs Advisory Committee	FR 2024-06314, published 2024-03-26
Mar 15, 2024	Oncologic Drugs Advisory Committee	FR 2024-02229, published 2024-02-05
Mar 14, 2024	Oncologic Drugs Advisory Committee	FR 2024-01797, published 2024-01-30
Mar 5, 2024	Medical Imaging Drugs Advisory Committee	FR 2024-01016, published 2024-01-19
Mar 5, 2024	Vaccines and Related Biological Products Advisory Committee	FR 2024-02709, published 2024-02-09

2023 · 41 notices

Meeting date	Committee	Federal Register notice
Nov 17, 2023	Pulmonary-Allergy Drugs Advisory Committee	FR 2023-19407, published 2023-09-08
Nov 16, 2023	Oncologic Drugs Advisory Committee	FR 2023-21984, published 2023-10-04
Oct 31, 2023	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2023-19284, published 2023-09-07
Oct 5, 2023	Oncologic Drugs Advisory Committee	FR 2023-18024, published 2023-08-22
Oct 5, 2023	Vaccines and Related Biological Products Advisory Committee	FR 2023-18243, published 2023-08-24
Oct 4, 2023	Oncologic Drugs Advisory Committee	FR 2023-17510, published 2023-08-16
Sep 27, 2023	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2023-15923, published 2023-07-27
Sep 21, 2023	Endocrinologic and Metabolic Drugs Advisory Committee	FR 2023-18250, published 2023-08-24
Sep 19 and Sep 20, 2023	Pediatric Advisory Committee	FR 2023-14923, published 2023-07-14
Sep 13, 2023	Cardiovascular and Renal Drugs Advisory Committee	FR 2023-14037, published 2023-07-03
Sep 11 and Sep 12, 2023	Nonprescription Drugs Advisory Committee	FR 2023-14713, published 2023-07-12
Sep 6, 2023	Patient Engagement Advisory Committee	FR 2023-10609, published 2023-05-18
Aug 1, 2023	Medical Imaging Drugs Advisory Committee	FR 2023-14460, published 2023-07-10
Jun 28, 2023	Endocrinologic and Metabolic Drugs Advisory Committee	FR 2023-11164, published 2023-05-25
Jun 16, 2023	Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	FR 2023-10051, published 2023-05-11
Jun 15, 2023	Vaccines and Related Biological Products Advisory Committee	FR 2023-09490, published 2023-05-04
Jun 9, 2023	Peripheral and Central Nervous System Drugs Advisory Committee	FR 2023-07526, published 2023-04-11
Jun 8, 2023	Antimicrobial Drugs Advisory Committee	FR 2023-09321, published 2023-05-03
May 19, 2023	Gastrointestinal Drugs Advisory Committee	FR 2023-05066, published 2023-03-13
May 18, 2023	Vaccines and Related Biological Products Advisory Committee	FR 2023-07550, published 2023-04-11
May 12, 2023	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2023-07518, published 2023-04-11
May 11, 2023	Pulmonary-Allergy Drugs Advisory Committee	FR 2023-06481, published 2023-03-29
May 9 and May 10, 2023	Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee	FR 2023-06524, published 2023-03-29
Apr 28, 2023	Oncologic Drugs Advisory Committee	FR 2023-04268, published 2023-03-02
Apr 26, 2023	Blood Products Advisory Committee	FR 2023-04270, published 2023-03-02
Apr 19, 2023	Anesthetic and Analgesic Drug Products Advisory Committee	FR 2023-03370, published 2023-02-17
Apr 17, 2023	Antimicrobial Drugs Advisory Committee	FR 2023-05068, published 2023-03-13
Apr 14, 2023	Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee	FR 2023-06577, published 2023-03-30
Apr 4 and Apr 5, 2023	Science Advisory Board to the National Center for Toxicological Research Advisory Committee	FR 2023-02095, published 2023-02-01
Mar 28, 2023	Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee	FR 2023-00795, published 2023-01-18
Mar 22, 2023	Peripheral and Central Nervous System Drugs Advisory Committee	FR 2023-01216, published 2023-01-24
Mar 20, 2023	Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	FR 2023-01761, published 2023-01-30
Mar 16, 2023	Antimicrobial Drugs Advisory Committee	FR 2023-03971, published 2023-02-27
Mar 9, 2023	Oncologic Drugs Advisory Committee	FR 2023-01553, published 2023-01-26
Mar 7, 2023	Vaccines and Related Biological Products Advisory Committee	FR 2023-02742, published 2023-02-09
Feb 28 and Mar 1, 2023	Vaccines and Related Biological Products Advisory Committee	FR 2023-02096, published 2023-02-01
Feb 15, 2023	Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	FR 2023-00110, published 2023-01-09
Feb 9, 2023	Oncologic Drugs Advisory Committee	FR 2022-27834, published 2022-12-22
Jan 26, 2023	Vaccines and Related Biological Products Advisory Committee	FR 2022-27428, published 2022-12-19
Jan 24, 2023	Antimicrobial Drugs Advisory Committee	FR 2022-25643, published 2022-11-25
Jan 9, 2023	Dermatologic and Ophthalmic Drugs Advisory Committee	FR 2022-25642, published 2022-11-25

2022 · 37 notices

Meeting date	Committee	Federal Register notice
Dec 14, 2022	Cardiovascular and Renal Drugs Advisory Committee	FR 2022-21775, published 2022-10-06
Dec 13, 2022	Cardiovascular and Renal Drugs Advisory Committee	FR 2022-21769, published 2022-10-06
Dec 8, 2022	Blood Products Advisory Committee	FR 2022-22612, published 2022-10-18
Dec 8, 2022	Science Board to the Food and Drug Administration Advisory Committee	FR 2022-25405, published 2022-11-22
Nov 22, 2022	Oncologic Drugs Advisory Committee	FR 2022-20524, published 2022-09-22
Nov 18, 2022	Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee	FR 2022-19718, published 2022-09-13
Nov 16, 2022	Cardiovascular and Renal Drugs Advisory Committee	FR 2022-20198, published 2022-09-19
Nov 9, 2022	Pulmonary-Allergy Drugs Advisory Committee (amended notice)	FR 2022-22700, published 2022-10-19
Nov 8, 2022	Pulmonary-Allergy Drugs Advisory Committee	FR 2022-19159, published 2022-09-06
Nov 2 and Nov 3, 2022	Pharmaceutical Science and Clinical Pharmacology Advisory Committee	FR 2022-18087, published 2022-08-23
Oct 31, 2022	Endocrinologic and Metabolic Drugs Advisory Committee	FR 2022-18143, published 2022-08-23
Oct 28, 2022	Oncologic Drugs Advisory Committee	FR 2022-19047, published 2022-09-02
Oct 26, 2022	Cardiovascular and Renal Drugs Advisory Committee	FR 2022-19156, published 2022-09-06
Oct 6, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-17784, published 2022-08-18
Oct 6, 2022	Pulmonary-Allergy Drugs Advisory Committee	FR 2022-19385, published 2022-09-08
Sep 22 and Sep 23, 2022	Oncologic Drugs Advisory Committee	FR 2022-15609, published 2022-07-21
Sep 22, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-17059, published 2022-08-09
Sep 7, 2022	Peripheral and Central Nervous System Drugs Advisory Committee	FR 2022-16570, published 2022-08-03
Jul 12 and Jul 13, 2022	Patient Engagement Advisory Committee	FR 2022-08013, published 2022-04-14
Jun 29 and Jun 30, 2022	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2022-11563, published 2022-05-31
Jun 28, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-11670, published 2022-05-31
Jun 17, 2022	Psychopharmacologic Drugs Advisory Committee	FR 2022-09433, published 2022-05-03
Jun 14, 2022	Science Board to the Food and Drug Administration Advisory Committee	FR 2022-10697, published 2022-05-18
Jun 9 and Jun 10, 2022	Cellular, Tissue and Gene Therapies Advisory Committee	FR 2022-08022, published 2022-04-14
Jun 8, 2022	Pharmacy Compounding Advisory Committee	FR 2022-09797, published 2022-05-06
Jun 7 and Jun 15, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-11669, published 2022-05-31
Jun 1 and Jun 7, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-11668, published 2022-05-31
May 18 and May 19, 2022	Science Advisory Board to the National Center for Toxicological Research Advisory Committee	FR 2022-08460, published 2022-04-20
May 11 and May 12, 2022	Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	FR 2022-07378, published 2022-04-07
Apr 21 and Apr 22, 2022	Oncologic Drugs Advisory Committee	FR 2022-05022, published 2022-03-10
Mar 31 and Apr 6, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-06053, published 2022-03-22
Mar 30, 2022	Peripheral and Central Nervous System Drugs Advisory Committee	FR 2022-03430, published 2022-02-17
Mar 10, 2022	Cellular, Tissue and Gene Therapies Advisory Committee	FR 2022-03366, published 2022-02-16
Mar 3, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-01368, published 2022-01-25
Feb 15, 2022	Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee	FR 2021-28474, published 2022-01-04
Feb 15, 2022	Vaccines and Related Biological Products Advisory Committee	FR 2022-02390, published 2022-02-04
Feb 10, 2022	Oncologic Drugs Advisory Committee	FR 2021-26891, published 2021-12-13

2021 · 28 notices

Meeting date	Committee	Federal Register notice
Dec 8, 2021	Cardiovascular and Renal Drugs Advisory Committee	FR 2021-20733, published 2021-09-24
Dec 2, 2021	Oncologic Drugs Advisory Committee	FR 2021-20740, published 2021-09-24
Nov 30, 2021	Antimicrobial Drugs Advisory Committee	FR 2021-23384, published 2021-10-27
Nov 4, 2021	Psychopharmacologic Drugs Advisory Committee	FR 2021-18892, published 2021-09-01
Nov 4, 2021	Blood Products Advisory Committee	FR 2021-19686, published 2021-09-13
Oct 28, 2021	Oncologic Drugs Advisory Committee	FR 2021-19024, published 2021-09-03
Oct 28, 2021	Allergenic Products Advisory Committee	FR 2021-19436, published 2021-09-09
Oct 21 and Oct 26, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-22452, published 2021-10-13
Oct 12 and Oct 14, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-22037, published 2021-10-07
Oct 7, 2021	Antimicrobial Drugs Advisory Committee	FR 2021-16356, published 2021-08-02
Oct 6, 2021	Patient Engagement Advisory Committee	FR 2021-17118, published 2021-08-11
Sep 30, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-18107, published 2021-08-24
Sep 17, 2021	Pediatric Advisory Committee	FR 2021-16984, published 2021-08-10
Sep 17, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-19394, published 2021-09-07
Sep 2, 2021	Cellular, Tissue and Gene Therapies Advisory Committee	FR 2021-15783, published 2021-07-26
Jul 15, 2021	Cardiovascular and Renal Drugs Advisory Committee	FR 2021-10751, published 2021-05-21
Jun 24, 2021	Oncologic Drugs Advisory Committee	FR 2021-10181, published 2021-05-14
Jun 10, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-10784, published 2021-05-21
Jun 9, 2021	Pharmacy Compounding Advisory Committee	FR 2021-09621, published 2021-05-07
May 27, 2021	Endocrinologic and Metabolic Drugs Advisory Committee	FR 2021-06708, published 2021-04-01
May 11 and May 12, 2021	Science Advisory Board to the National Center for Toxicological Research Advisory Committee	FR 2021-06930, published 2021-04-05
May 11 and May 12, 2021	Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	FR 2021-07546, published 2021-04-13
May 6, 2021	Arthritis Advisory Committee	FR 2021-06265, published 2021-03-26
Apr 27 and Apr 29, 2021	Oncologic Drugs Advisory Committee	FR 2021-05202, published 2021-03-12
Mar 24 and Mar 25, 2021	Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee	FR 2021-03068, published 2021-02-16
Mar 5, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-03014, published 2021-02-16
Feb 26, 2021	Vaccines and Related Biological Products Advisory Committee	FR 2021-02845, published 2021-02-11
Feb 9, 2021	Oncologic Drugs Advisory Committee	FR 2020-28558, published 2020-12-28

2020 · 29 notices

Meeting date	Committee	Federal Register notice
Dec 17, 2020	Vaccines and Related Biological Products Advisory Committee	FR 2020-26704, published 2020-12-03
Dec 16, 2020	Cardiovascular and Renal Drugs Advisory Committee	FR 2020-23843, published 2020-10-28
Dec 15, 2020	Cardiovascular and Renal Drugs Advisory Committee	FR 2020-23842, published 2020-10-28
Dec 10, 2020	Vaccines and Related Biological Products Advisory Committee	FR 2020-26229, published 2020-11-27
Nov 6, 2020	Peripheral and Central Nervous System Drugs Advisory Committee	FR 2020-21448, published 2020-09-29
Nov 2, 2020	Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee	FR 2020-22187, published 2020-10-07
Oct 22, 2020	Patient Engagement Advisory Committee	FR 2020-18953, published 2020-08-28
Oct 22, 2020	Vaccines and Related Biological Products Advisory Committee	FR 2020-18985, published 2020-08-28
Oct 9, 2020	Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee	FR 2020-18951, published 2020-08-28
Oct 8, 2020	Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee	FR 2020-19562, published 2020-09-04
Oct 2, 2020	Vaccines and Related Biological Products Advisory Committee	FR 2020-17495, published 2020-08-11
·	Vaccines and Related Biological Products Advisory Committee (amended notice)	FR 2020-21630, published 2020-09-30
Sep 15, 2020	Pediatric Advisory Committee	FR 2020-15998, published 2020-07-23
Sep 10 and Sep 11, 2020	Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	FR 2020-18752, published 2020-08-26
Aug 31, 2020	Pulmonary-Allergy Drugs Advisory Committee	FR 2020-17533, published 2020-08-11
Aug 18 and Aug 19, 2020	Science Advisory Board to the National Center for Toxicological Research Advisory Committee	FR 2020-15524, published 2020-07-17
·	Pediatric Advisory Committee (amended notice)	FR 2020-17775, published 2020-08-14
Aug 13, 2020	Oncologic Drugs Advisory Committee	FR 2020-15719, published 2020-07-21
Jul 15, 2020	Cardiovascular and Renal Drugs Advisory Committee	FR 2020-14719, published 2020-07-08
Jul 14, 2020	Oncologic Drugs Advisory Committee	FR 2020-13345, published 2020-06-22
Jun 17 and Jun 18, 2020	Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	FR 2020-11883, published 2020-06-02
May 15, 2020	Allergenic Products Advisory Committee	FR 2020-03604, published 2020-02-24
May 8, 2020	Cellular, Tissue, and Gene Therapies Advisory Committee	FR 2020-05333, published 2020-03-16
Apr 23, 2020	Medical Imaging Drugs Advisory Committee	FR 2020-03424, published 2020-02-20
Apr 21, 2020	Pulmonary-Allergy Drugs Advisory Committee	FR 2020-03410, published 2020-02-20
Apr 2 and Apr 3, 2020	Blood Products Advisory Committee	FR 2020-02873, published 2020-02-13
Mar 11, 2020	Nonprescription Drugs Advisory Committee	FR 2020-02244, published 2020-02-05
Mar 4, 2020	Vaccines and Related Biological Products Advisory Committee	FR 2019-28508, published 2020-01-06
Feb 26, 2020	Oncologic Drugs Advisory Committee	FR 2020-01150, published 2020-01-24

Questions

What is an FDA advisory committee?

A panel of outside experts convened to review an application's evidence and vote on questions the FDA poses.

Is the FDA bound by the vote?

No. The vote is advisory; the FDA usually follows it but is free not to.

How many meetings are on record here?

187 FDA advisory committee meetings announced in the Federal Register since January 2020 are listed, each linked to its notice; 2 of them are documented with their votes and outcomes as of October 11, 2026.

About · Corrections · Changelog · Glossary · Methodology

Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.

Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.

© 2026 pdufa.bio. All rights reserved.